Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Thrombosis Research|December 1, 2009
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptorsHung Chang, Ivan B Yanachkov, Alan D Michelson, et al.
Platelets|August 13, 2010
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney functionMaria Lajer, Inge Tarnow, Alan D Michelson, et al.
Scientific Reports|December 1, 2018
Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet ActivationElena Smolensky Koganov, Alan D Michelson, Ivan B Yanachkov, et al.
Scientific Reports|September 30, 2018
GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet ActivationElena Smolensky Koganov, Alan D Michelson, Ivan B Yanachkov, et al.
Circulation|June 21, 2006
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistanceAndrew L Frelinger, Mark I Furman, Matthew D Linden, et al.
Plos One|April 23, 2021
Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobinBogdan Neculaes, Andrew L Frelinger, Anja J Gerrits, et al.
Atherosclerosis|November 22, 2021
Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterizationThomas Gremmel, Alan D Michelson, Patricia P Wadowski, et al.
Haematologica|July 11, 2019
Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin: the role of phosphodiesterase 3AMartin Berger, Zaher Raslan, Ahmed Aburima, et al.
Clinical and Translational Science|January 1, 2019
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled StudyRobert J Charnigo, David Beidler, Denis Rybin, et al.
Thrombosis Research|May 29, 2007
Cystic fibrosis heterozygotes do not have increased platelet activationInge Tarnow, Alan D Michelson, Andrew L Frelinger, et al.
Pageof 11